| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 36 | 2025 | 124 | 8.260 |
Why?
|
| Robotic Surgical Procedures | 19 | 2025 | 232 | 7.540 |
Why?
|
| Liver Neoplasms | 39 | 2025 | 1417 | 6.530 |
Why?
|
| Bile Duct Neoplasms | 12 | 2025 | 121 | 5.290 |
Why?
|
| Cholangiocarcinoma | 11 | 2024 | 121 | 5.080 |
Why?
|
| Pancreatic Neoplasms | 32 | 2025 | 738 | 4.620 |
Why?
|
| Laparoscopy | 12 | 2025 | 520 | 4.590 |
Why?
|
| Colorectal Neoplasms | 21 | 2025 | 652 | 4.490 |
Why?
|
| Biliary Tract Neoplasms | 6 | 2025 | 21 | 2.880 |
Why?
|
| Pancreatectomy | 14 | 2025 | 152 | 2.410 |
Why?
|
| Neoadjuvant Therapy | 19 | 2024 | 406 | 2.340 |
Why?
|
| Robotics | 5 | 2022 | 110 | 2.240 |
Why?
|
| Carcinoma, Hepatocellular | 9 | 2024 | 1007 | 2.080 |
Why?
|
| Neoplasm Staging | 16 | 2025 | 1391 | 1.910 |
Why?
|
| Chemoradiotherapy, Adjuvant | 6 | 2024 | 34 | 1.740 |
Why?
|
| Adenocarcinoma | 12 | 2022 | 1071 | 1.710 |
Why?
|
| Gallbladder Neoplasms | 4 | 2025 | 15 | 1.590 |
Why?
|
| Bile Ducts, Intrahepatic | 8 | 2023 | 105 | 1.510 |
Why?
|
| Liver | 8 | 2025 | 1879 | 1.430 |
Why?
|
| Carcinoembryonic Antigen | 3 | 2024 | 23 | 1.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2024 | 1356 | 1.240 |
Why?
|
| Retrospective Studies | 56 | 2025 | 17540 | 1.230 |
Why?
|
| Humans | 134 | 2025 | 134156 | 1.220 |
Why?
|
| Portal Vein | 6 | 2024 | 95 | 1.220 |
Why?
|
| Carcinoma | 4 | 2012 | 322 | 1.160 |
Why?
|
| Postoperative Complications | 12 | 2025 | 3178 | 1.110 |
Why?
|
| Embolization, Therapeutic | 4 | 2024 | 225 | 1.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2022 | 167 | 1.070 |
Why?
|
| Propensity Score | 3 | 2024 | 261 | 1.040 |
Why?
|
| Lymph Node Excision | 4 | 2022 | 176 | 1.030 |
Why?
|
| Chemotherapy, Adjuvant | 10 | 2019 | 401 | 1.020 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2025 | 87 | 1.000 |
Why?
|
| Survival Rate | 18 | 2025 | 2218 | 0.990 |
Why?
|
| Cholecystectomy | 3 | 2025 | 64 | 0.990 |
Why?
|
| Green Fluorescent Proteins | 4 | 2010 | 402 | 0.940 |
Why?
|
| Lymph Nodes | 6 | 2023 | 399 | 0.940 |
Why?
|
| Middle Aged | 48 | 2025 | 29399 | 0.920 |
Why?
|
| Aged | 43 | 2025 | 21775 | 0.920 |
Why?
|
| Klatskin Tumor | 2 | 2025 | 6 | 0.900 |
Why?
|
| Biliary Tract Surgical Procedures | 4 | 2024 | 23 | 0.870 |
Why?
|
| Diagnostic Imaging | 6 | 2016 | 317 | 0.850 |
Why?
|
| Fluorescent Dyes | 5 | 2022 | 271 | 0.840 |
Why?
|
| Rectal Neoplasms | 5 | 2023 | 81 | 0.820 |
Why?
|
| Insurance | 1 | 2023 | 8 | 0.820 |
Why?
|
| Pancreaticoduodenectomy | 10 | 2023 | 106 | 0.790 |
Why?
|
| Hospitals | 3 | 2020 | 437 | 0.780 |
Why?
|
| Treatment Outcome | 27 | 2025 | 13074 | 0.750 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 563 | 0.730 |
Why?
|
| Prognosis | 20 | 2025 | 5086 | 0.710 |
Why?
|
| Fluorescence | 7 | 2021 | 102 | 0.700 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2021 | 44 | 0.690 |
Why?
|
| Immunoconjugates | 1 | 2021 | 46 | 0.690 |
Why?
|
| Thyroid Neoplasms | 3 | 2016 | 262 | 0.680 |
Why?
|
| Female | 62 | 2025 | 71928 | 0.670 |
Why?
|
| Minimally Invasive Surgical Procedures | 9 | 2024 | 195 | 0.670 |
Why?
|
| Surgery, Computer-Assisted | 3 | 2022 | 64 | 0.660 |
Why?
|
| Lymphatic Metastasis | 6 | 2021 | 453 | 0.650 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2019 | 168 | 0.630 |
Why?
|
| Nutrition Assessment | 1 | 2020 | 138 | 0.630 |
Why?
|
| Mice, Nude | 13 | 2022 | 780 | 0.630 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 170 | 0.620 |
Why?
|
| Analgesics, Opioid | 5 | 2025 | 465 | 0.620 |
Why?
|
| Male | 53 | 2025 | 66127 | 0.610 |
Why?
|
| Preoperative Care | 2 | 2020 | 376 | 0.600 |
Why?
|
| Length of Stay | 9 | 2025 | 1391 | 0.600 |
Why?
|
| Surgical Wound Infection | 3 | 2023 | 275 | 0.590 |
Why?
|
| Hernia, Abdominal | 1 | 2018 | 19 | 0.580 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2024 | 2198 | 0.580 |
Why?
|
| Malnutrition | 2 | 2020 | 221 | 0.570 |
Why?
|
| Patient Care Planning | 1 | 2019 | 133 | 0.560 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2025 | 1317 | 0.560 |
Why?
|
| Biomarkers, Tumor | 6 | 2025 | 1721 | 0.530 |
Why?
|
| Gastrectomy | 6 | 2024 | 103 | 0.510 |
Why?
|
| Ultrasonography | 2 | 2019 | 1004 | 0.490 |
Why?
|
| Neoplasms | 7 | 2024 | 3038 | 0.490 |
Why?
|
| Pancreatic Cyst | 2 | 2019 | 28 | 0.480 |
Why?
|
| Follow-Up Studies | 14 | 2025 | 5477 | 0.480 |
Why?
|
| Stomach Neoplasms | 5 | 2024 | 566 | 0.470 |
Why?
|
| Mesenteric Veins | 2 | 2020 | 14 | 0.470 |
Why?
|
| Proportional Hazards Models | 6 | 2024 | 1488 | 0.470 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 165 | 0.470 |
Why?
|
| Liver Diseases | 1 | 2019 | 392 | 0.460 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2024 | 3857 | 0.460 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2012 | 434 | 0.460 |
Why?
|
| Breast Neoplasms | 3 | 2021 | 2771 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2025 | 772 | 0.440 |
Why?
|
| Adult | 28 | 2025 | 31945 | 0.430 |
Why?
|
| Pancreatic Diseases | 1 | 2014 | 40 | 0.430 |
Why?
|
| Microscopy, Fluorescence | 3 | 2010 | 337 | 0.430 |
Why?
|
| Neuroendocrine Tumors | 3 | 2025 | 56 | 0.410 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 1310 | 0.410 |
Why?
|
| Colonic Neoplasms | 4 | 2022 | 272 | 0.400 |
Why?
|
| Cell Line, Tumor | 10 | 2022 | 3798 | 0.380 |
Why?
|
| Quality Indicators, Health Care | 2 | 2017 | 231 | 0.380 |
Why?
|
| Drainage | 3 | 2018 | 265 | 0.370 |
Why?
|
| Cohort Studies | 9 | 2022 | 5222 | 0.370 |
Why?
|
| Neoplasms, Experimental | 2 | 2010 | 224 | 0.370 |
Why?
|
| Lymphatic System | 1 | 2011 | 21 | 0.360 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 746 | 0.360 |
Why?
|
| Thyroid Gland | 1 | 2012 | 117 | 0.360 |
Why?
|
| Aged, 80 and over | 12 | 2025 | 7217 | 0.360 |
Why?
|
| SEER Program | 1 | 2012 | 224 | 0.350 |
Why?
|
| Skin, Artificial | 1 | 2010 | 8 | 0.350 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2010 | 88 | 0.330 |
Why?
|
| Patient Selection | 3 | 2025 | 735 | 0.330 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2025 | 1012 | 0.330 |
Why?
|
| Mammaplasty | 1 | 2010 | 54 | 0.330 |
Why?
|
| Carcinoma, Papillary | 1 | 2010 | 96 | 0.330 |
Why?
|
| Mammography | 1 | 2010 | 133 | 0.320 |
Why?
|
| United States | 14 | 2024 | 11763 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 2 | 2013 | 1072 | 0.320 |
Why?
|
| Pancreas, Exocrine | 1 | 2009 | 5 | 0.310 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2019 | 1146 | 0.310 |
Why?
|
| Collagen | 1 | 2010 | 330 | 0.310 |
Why?
|
| Pain, Postoperative | 4 | 2025 | 278 | 0.300 |
Why?
|
| Patient Discharge | 2 | 2023 | 519 | 0.300 |
Why?
|
| Prospective Studies | 8 | 2024 | 6601 | 0.300 |
Why?
|
| Drug Prescriptions | 3 | 2025 | 240 | 0.290 |
Why?
|
| Anus Neoplasms | 2 | 2018 | 42 | 0.280 |
Why?
|
| Disease Models, Animal | 5 | 2025 | 4808 | 0.280 |
Why?
|
| Liver Regeneration | 2 | 2024 | 41 | 0.280 |
Why?
|
| Disease-Free Survival | 4 | 2021 | 972 | 0.270 |
Why?
|
| Patient Readmission | 2 | 2023 | 429 | 0.260 |
Why?
|
| Bayes Theorem | 3 | 2022 | 316 | 0.260 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 1440 | 0.260 |
Why?
|
| Colonoscopy | 1 | 2009 | 249 | 0.260 |
Why?
|
| Mice | 16 | 2025 | 19055 | 0.260 |
Why?
|
| Deoxycytidine | 3 | 2018 | 84 | 0.260 |
Why?
|
| Databases, Factual | 5 | 2024 | 1258 | 0.250 |
Why?
|
| Young Adult | 8 | 2021 | 9944 | 0.250 |
Why?
|
| Predictive Value of Tests | 6 | 2024 | 2301 | 0.240 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2024 | 222 | 0.240 |
Why?
|
| Critical Pathways | 2 | 2022 | 79 | 0.230 |
Why?
|
| Medical Futility | 1 | 2025 | 39 | 0.230 |
Why?
|
| Hepatic Veins | 1 | 2024 | 24 | 0.230 |
Why?
|
| Organ Sparing Treatments | 1 | 2025 | 45 | 0.230 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 385 | 0.230 |
Why?
|
| Tumor Burden | 4 | 2021 | 259 | 0.230 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 396 | 0.230 |
Why?
|
| Surgical Instruments | 1 | 2024 | 57 | 0.230 |
Why?
|
| Animals | 18 | 2025 | 36557 | 0.220 |
Why?
|
| Ipilimumab | 1 | 2024 | 61 | 0.220 |
Why?
|
| Risk Assessment | 5 | 2023 | 3743 | 0.220 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2024 | 53 | 0.210 |
Why?
|
| Surgical Oncology | 2 | 2020 | 13 | 0.210 |
Why?
|
| Cholangitis | 1 | 2024 | 40 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2025 | 178 | 0.210 |
Why?
|
| Incisional Hernia | 1 | 2023 | 5 | 0.210 |
Why?
|
| Radiotherapy Dosage | 1 | 2024 | 231 | 0.210 |
Why?
|
| Point Mutation | 1 | 2025 | 362 | 0.210 |
Why?
|
| Nutritional Status | 3 | 2020 | 325 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 675 | 0.210 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 1492 | 0.210 |
Why?
|
| Receptors, Somatostatin | 2 | 2022 | 56 | 0.200 |
Why?
|
| Hospital Costs | 1 | 2024 | 187 | 0.200 |
Why?
|
| Hypertension, Portal | 1 | 2024 | 81 | 0.200 |
Why?
|
| Cisplatin | 2 | 2023 | 287 | 0.200 |
Why?
|
| Mutation | 8 | 2025 | 6338 | 0.200 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 158 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 1340 | 0.190 |
Why?
|
| Teaching Rounds | 1 | 2022 | 30 | 0.190 |
Why?
|
| Hospital Mortality | 2 | 2020 | 1096 | 0.190 |
Why?
|
| Social Class | 1 | 2023 | 210 | 0.190 |
Why?
|
| Pancreatitis, Chronic | 1 | 2022 | 76 | 0.190 |
Why?
|
| Adolescent | 8 | 2021 | 20624 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 872 | 0.190 |
Why?
|
| Luminescent Proteins | 3 | 2010 | 166 | 0.180 |
Why?
|
| Neoplasm Transplantation | 3 | 2011 | 399 | 0.180 |
Why?
|
| Precision Medicine | 1 | 2025 | 357 | 0.180 |
Why?
|
| Cholangiography | 1 | 2021 | 15 | 0.180 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 16 | 0.180 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2024 | 399 | 0.180 |
Why?
|
| Coloring Agents | 1 | 2021 | 78 | 0.180 |
Why?
|
| Indocyanine Green | 1 | 2021 | 62 | 0.170 |
Why?
|
| Technology | 1 | 2021 | 71 | 0.170 |
Why?
|
| Fluorouracil | 2 | 2018 | 141 | 0.170 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 3754 | 0.170 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 51 | 0.170 |
Why?
|
| Chemoradiotherapy | 2 | 2018 | 127 | 0.170 |
Why?
|
| Trastuzumab | 1 | 2021 | 154 | 0.170 |
Why?
|
| Survival Analysis | 3 | 2021 | 1599 | 0.160 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 920 | 0.160 |
Why?
|
| Positron-Emission Tomography | 2 | 2019 | 311 | 0.160 |
Why?
|
| Gallium Radioisotopes | 1 | 2019 | 7 | 0.160 |
Why?
|
| Device Removal | 2 | 2018 | 223 | 0.160 |
Why?
|
| Quality of Life | 4 | 2019 | 2160 | 0.160 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 1979 | 0.150 |
Why?
|
| Software | 1 | 2024 | 735 | 0.150 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 285 | 0.150 |
Why?
|
| Streptozocin | 1 | 2018 | 28 | 0.150 |
Why?
|
| Radiopharmaceuticals | 1 | 2019 | 171 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 481 | 0.150 |
Why?
|
| Fascia | 1 | 2018 | 16 | 0.150 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2019 | 136 | 0.150 |
Why?
|
| Incidental Findings | 1 | 2019 | 129 | 0.150 |
Why?
|
| Clinical Enzyme Tests | 1 | 2018 | 17 | 0.140 |
Why?
|
| Amylases | 1 | 2018 | 25 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 298 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2022 | 1493 | 0.140 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2024 | 89 | 0.140 |
Why?
|
| Disease Progression | 4 | 2013 | 2266 | 0.140 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 1853 | 0.140 |
Why?
|
| Doxorubicin | 1 | 2018 | 303 | 0.130 |
Why?
|
| Receptor, ErbB-2 | 1 | 2021 | 559 | 0.130 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2016 | 10 | 0.130 |
Why?
|
| Mice, Transgenic | 4 | 2013 | 2539 | 0.130 |
Why?
|
| Pancreatic Fistula | 3 | 2022 | 30 | 0.130 |
Why?
|
| Confidence Intervals | 1 | 2017 | 300 | 0.130 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 116 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 128 | 0.130 |
Why?
|
| Nutritional Support | 1 | 2017 | 57 | 0.130 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2016 | 39 | 0.130 |
Why?
|
| Operative Time | 3 | 2023 | 189 | 0.130 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 947 | 0.130 |
Why?
|
| Thyroid Nodule | 1 | 2016 | 21 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 203 | 0.120 |
Why?
|
| Survivors | 2 | 2016 | 358 | 0.120 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 139 | 0.120 |
Why?
|
| Comorbidity | 3 | 2019 | 1625 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2022 | 1062 | 0.120 |
Why?
|
| Risk Factors | 6 | 2025 | 11182 | 0.110 |
Why?
|
| Defecation | 1 | 2014 | 34 | 0.110 |
Why?
|
| Incidence | 2 | 2023 | 3416 | 0.110 |
Why?
|
| Hospital Charges | 1 | 2014 | 63 | 0.110 |
Why?
|
| Splenectomy | 1 | 2014 | 63 | 0.110 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 114 | 0.100 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2013 | 24 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 65 | 0.100 |
Why?
|
| Margins of Excision | 2 | 2025 | 59 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 1409 | 0.100 |
Why?
|
| Pancreatitis | 1 | 2014 | 144 | 0.100 |
Why?
|
| Hospitalization | 1 | 2021 | 1906 | 0.090 |
Why?
|
| Time Factors | 4 | 2018 | 6610 | 0.090 |
Why?
|
| Integrin beta1 | 1 | 2011 | 56 | 0.090 |
Why?
|
| Subtraction Technique | 1 | 2010 | 36 | 0.090 |
Why?
|
| Cell Line | 3 | 2010 | 2864 | 0.090 |
Why?
|
| Cell Proliferation | 4 | 2011 | 2563 | 0.090 |
Why?
|
| Whole Body Imaging | 1 | 2010 | 31 | 0.090 |
Why?
|
| Xenon | 1 | 2010 | 13 | 0.090 |
Why?
|
| Pseudopodia | 1 | 2010 | 9 | 0.080 |
Why?
|
| Lighting | 1 | 2010 | 19 | 0.080 |
Why?
|
| Mastectomy, Segmental | 1 | 2010 | 40 | 0.080 |
Why?
|
| Accidents, Traffic | 1 | 2011 | 111 | 0.080 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 90 | 0.080 |
Why?
|
| Rectum | 2 | 2023 | 113 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 2172 | 0.080 |
Why?
|
| Drug Synergism | 1 | 2010 | 242 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 1787 | 0.080 |
Why?
|
| Antibodies | 1 | 2011 | 382 | 0.080 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 276 | 0.080 |
Why?
|
| Polymers | 1 | 2010 | 118 | 0.080 |
Why?
|
| Image Enhancement | 1 | 2010 | 173 | 0.080 |
Why?
|
| Thrombospondin 1 | 1 | 2009 | 25 | 0.080 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 296 | 0.080 |
Why?
|
| Cytoskeleton | 1 | 2010 | 175 | 0.080 |
Why?
|
| Indoles | 1 | 2010 | 203 | 0.080 |
Why?
|
| Histocytochemistry | 1 | 2009 | 98 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2010 | 235 | 0.080 |
Why?
|
| Pyrroles | 1 | 2010 | 187 | 0.080 |
Why?
|
| California | 1 | 2009 | 144 | 0.080 |
Why?
|
| Ascites | 1 | 2009 | 111 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 232 | 0.070 |
Why?
|
| General Surgery | 1 | 2011 | 217 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 263 | 0.070 |
Why?
|
| Cell Survival | 1 | 2010 | 890 | 0.070 |
Why?
|
| Inpatients | 2 | 2022 | 547 | 0.070 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 307 | 0.070 |
Why?
|
| Wounds and Injuries | 1 | 2011 | 394 | 0.070 |
Why?
|
| Nanoparticles | 1 | 2010 | 290 | 0.070 |
Why?
|
| Lower Body Negative Pressure | 1 | 2006 | 5 | 0.070 |
Why?
|
| Models, Animal | 1 | 2009 | 486 | 0.070 |
Why?
|
| Hospitals, Veterans | 1 | 2009 | 364 | 0.070 |
Why?
|
| Lipids | 1 | 2010 | 566 | 0.060 |
Why?
|
| Betacoronavirus | 2 | 2020 | 306 | 0.060 |
Why?
|
| Gastrointestinal Tract | 1 | 2009 | 243 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1740 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2578 | 0.060 |
Why?
|
| Biomarkers | 3 | 2023 | 3434 | 0.060 |
Why?
|
| Quality Improvement | 2 | 2025 | 700 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2006 | 317 | 0.060 |
Why?
|
| Exercise Test | 1 | 2006 | 264 | 0.060 |
Why?
|
| Age Factors | 1 | 2012 | 2998 | 0.060 |
Why?
|
| Pain | 2 | 2023 | 476 | 0.060 |
Why?
|
| Abdominal Muscles | 1 | 2023 | 30 | 0.050 |
Why?
|
| Learning Curve | 1 | 2024 | 57 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2013 | 4879 | 0.050 |
Why?
|
| Bilirubin | 1 | 2024 | 131 | 0.050 |
Why?
|
| Observer Variation | 1 | 2024 | 314 | 0.050 |
Why?
|
| Pancreaticojejunostomy | 1 | 2022 | 6 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2024 | 239 | 0.050 |
Why?
|
| Organ Size | 1 | 2024 | 467 | 0.050 |
Why?
|
| Hepatic Artery | 1 | 2022 | 51 | 0.050 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2022 | 34 | 0.050 |
Why?
|
| Pandemics | 2 | 2020 | 1190 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 1218 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 127 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2024 | 252 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 147 | 0.050 |
Why?
|
| Texas | 2 | 2021 | 3716 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2023 | 201 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 3043 | 0.050 |
Why?
|
| Registries | 2 | 2019 | 1578 | 0.050 |
Why?
|
| Genes, APC | 1 | 2021 | 13 | 0.040 |
Why?
|
| Radiology, Interventional | 1 | 2021 | 35 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 185 | 0.040 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2020 | 24 | 0.040 |
Why?
|
| Operating Rooms | 1 | 2021 | 75 | 0.040 |
Why?
|
| Genes, ras | 1 | 2021 | 102 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2024 | 408 | 0.040 |
Why?
|
| Consensus | 1 | 2024 | 732 | 0.040 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2020 | 7 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 2020 | 14 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2021 | 234 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2025 | 797 | 0.040 |
Why?
|
| Patient Safety | 1 | 2024 | 433 | 0.040 |
Why?
|
| Peritoneal Neoplasms | 1 | 2020 | 55 | 0.040 |
Why?
|
| Chelating Agents | 1 | 2019 | 47 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 148 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2019 | 90 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 843 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 649 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2021 | 628 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2019 | 402 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2022 | 8623 | 0.040 |
Why?
|
| Colon, Ascending | 1 | 2018 | 8 | 0.040 |
Why?
|
| Colon, Sigmoid | 1 | 2018 | 14 | 0.040 |
Why?
|
| Neomycin | 1 | 2018 | 37 | 0.040 |
Why?
|
| Anal Canal | 1 | 2018 | 82 | 0.040 |
Why?
|
| Cathartics | 1 | 2018 | 31 | 0.040 |
Why?
|
| Anastomotic Leak | 1 | 2018 | 33 | 0.040 |
Why?
|
| Citric Acid | 1 | 2018 | 38 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 698 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 210 | 0.030 |
Why?
|
| Sarcoma | 1 | 2020 | 209 | 0.030 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 113 | 0.030 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 13 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 1107 | 0.030 |
Why?
|
| Metronidazole | 1 | 2018 | 157 | 0.030 |
Why?
|
| Cytokines | 1 | 2023 | 1401 | 0.030 |
Why?
|
| Prevalence | 1 | 2024 | 2684 | 0.030 |
Why?
|
| Cell Movement | 2 | 2011 | 920 | 0.030 |
Why?
|
| Stomach | 1 | 2019 | 272 | 0.030 |
Why?
|
| Infant | 1 | 2012 | 13240 | 0.030 |
Why?
|
| Pancreas | 1 | 2017 | 232 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2012 | 14884 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 574 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 727 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2016 | 121 | 0.030 |
Why?
|
| Thyroidectomy | 1 | 2016 | 112 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 1338 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 964 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 701 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1200 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2021 | 4934 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 258 | 0.030 |
Why?
|
| Melanoma | 1 | 2020 | 967 | 0.020 |
Why?
|
| Child | 1 | 2012 | 25890 | 0.020 |
Why?
|
| Focal Adhesions | 1 | 2010 | 14 | 0.020 |
Why?
|
| Phosphotyrosine | 1 | 2010 | 31 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2011 | 161 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 361 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 399 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2010 | 97 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2010 | 143 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 363 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2011 | 338 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 672 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 723 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 837 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 993 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 3114 | 0.020 |
Why?
|
| Actins | 1 | 2010 | 353 | 0.020 |
Why?
|
| Hypergravity | 1 | 2006 | 2 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 806 | 0.020 |
Why?
|
| Weight-Bearing | 1 | 2006 | 45 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 1332 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2009 | 915 | 0.020 |
Why?
|
| Proteomics | 1 | 2010 | 599 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 1071 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 3180 | 0.020 |
Why?
|
| Computational Biology | 1 | 2010 | 890 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 3999 | 0.010 |
Why?
|
| Heart Rate | 1 | 2006 | 601 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2009 | 2915 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 1923 | 0.010 |
Why?
|